Akums Drugs & Pharmaceuticals Q2 Results FY27: Revenue Up 31.93% to Rs 1,342.39 Cr, PAT Up 168.31% to Rs 114.57 Cr
- November 2, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Akums Drugs & Pharmaceuticals Q2 Results FY27 were declared on 2 November 2026. Consolidated revenue reached Rs 1,342.39 Cr, up 31.93% from Rs 1,017.53 Cr a year earlier, while net profit rose 168.31% to Rs 114.57 Cr from Rs 42.70 Cr. Operating Profit was Rs 194.73 Cr. These quarterly results show YoY growth across all three lines.
Akums Drugs & Pharmaceuticals Ltd (AKUMS) Q2 Results FY27 announced on 2 November 2026, covering the company’s financial performance for the July to September quarter. The Consolidated figures show revenue of Rs 1,342.39 Cr and PAT of Rs 114.57 Cr. With the results date now on record, Akums Drugs & Pharmaceuticals Q2 Results FY27 give investors a full set of comparable numbers from NSE and BSE filings, and the consolidated results show higher revenue and profit.
This results analysis of Akums Drugs & Pharmaceuticals Q2 Results walks through the financial highlights, business drivers, outlook and risks behind the headline figures. Univest presents the numbers in the sequence most readers follow, beginning with the Financial Highlights table placed directly below.
Click Here – Get Free Investment Predictions
Akums Drugs & Pharmaceuticals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 1342.39 Cr | Rs 1017.53 Cr | +31.93% YoY |
| Operating Profit | Rs 194.73 Cr | Rs 94.48 Cr | +106.11% YoY |
| Net Profit (PAT) | Rs 114.57 Cr | Rs 42.7 Cr | +168.31% YoY |
Source: company filing for Akums Drugs & Pharmaceuticals Q2 Results FY27, 2 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Akums Drugs & Pharmaceuticals Q2 Results: What Stands Out
- Revenue climbed to Rs 1,342.39 Cr from Rs 1,017.53 Cr in the corresponding quarter of last year, a rise of 31.93% on the Consolidated basis.
- Net profit reached Rs 114.57 Cr against Rs 42.70 Cr a year earlier, so YoY growth of 168.31% outpaced the revenue gain in Akums Drugs & Pharmaceuticals Q2 Results FY27.
- Operating Profit stood at Rs 194.73 Cr compared with Rs 94.48 Cr, an increase of 106.11% over the prior-year quarter.
- Net profit margin improved to 8.5% from 4.2% in the comparison quarter, showing more profit retained from each rupee of sales.
- Up next, the performance analysis places revenue, Operating Profit and PAT side by side for a closer comparison.
Akums Drugs & Pharmaceuticals Q2 Results FY27: Performance Analysis
The figures show growth on every reported line. Akums Drugs & Pharmaceuticals earned Consolidated revenue of Rs 1,342.39 Cr against Rs 1,017.53 Cr, up 31.93%, and net profit of Rs 114.57 Cr against Rs 42.70 Cr, up 168.31%. Operating Profit rose 106.11% to Rs 194.73 Cr.
Within Akums Drugs & Pharmaceuticals Q2 Results FY27, revenue added Rs 324.86 Cr over the year-ago quarter while net profit added Rs 71.87 Cr, which is why the net profit margin moved from 4.2% to 8.5%. Operating Profit more than doubled from Rs 94.48 Cr, and PAT grew faster than sales.
Investors reading Akums Drugs & Pharmaceuticals Q2 Results will notice that the profit lines grew at a higher rate than revenue. This results analysis therefore treats YoY growth in earnings as the main feature of the quarterly results, and the business factors below set out what the data discloses alongside it.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – Revenue grew 31.9% year on year to Rs 1,342.39 Cr in the latest quarter, the disclosed top-line factor behind Akums Drugs & Pharmaceuticals Q2 Results FY27 and the base on which the profit lines were built.
Net Profit and Margin – Net profit rose 168.3% year on year to Rs 114.57 Cr, and the net profit margin improved to 8.5% from 4.2% in the comparison quarter, so earnings expanded faster than sales.
Balance Sheet Position – The company is almost debt free, with a debt-to-assets ratio of 0.02 in FY26, a full-year measure that sits alongside the quarterly numbers without altering any figure reported for the three months.
FY27 Outlook After Akums Drugs & Pharmaceuticals Q2 Results
The FY27 picture will build on the figures reported for July to September 2026, which include revenue of Rs 1,342.39 Cr and net profit of Rs 114.57 Cr. Full-year results for FY27 depend on the quarters still to come and on sector conditions disclosed in later filings.
For Akums Drugs & Pharmaceuticals Q2 Results FY27, the useful reference points ahead are whether revenue holds near Rs 1,342.39 Cr, whether Operating Profit stays close to Rs 194.73 Cr, and how net profit compares with Rs 114.57 Cr. Readers using the Univest app or Univest Screener can follow those points as new results appear, and the risks come next.
Key Risks to Watch After Akums Drugs & Pharmaceuticals Q2 Results FY27
Low Return on Equity
Return on equity was low at 8.06% in FY26. After Akums Drugs & Pharmaceuticals Q2 Results FY27, this full-year ratio is a useful check on how much profit the company earns on shareholder capital.
Volatile Quarterly Profit
Quarterly net profit has been volatile, ranging from Rs 42.70 Cr to Rs 114.57 Cr over the last 5 quarters. That spread means a single quarter of YoY growth may not set the pattern for the next one.
Decline in Return on Equity
Return on equity declined to 8.06% in FY26 from 18.30% in FY25. The fall of 10.24 percentage points in the full-year ratio contrasts with the sharp rise in quarterly profit and deserves watching.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Akums Drugs & Pharmaceuticals Q2 Results FY27 show Consolidated revenue of Rs 1,342.39 Cr, up 31.93%, and net profit of Rs 114.57 Cr, up 168.31%. These quarterly results record growth on every reported line. Readers following Akums Drugs & Pharmaceuticals Q2 Results should compare later filings with these consolidated results and consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Akums Drugs & Pharmaceuticals Q2 Results FY27
What are Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. Akums Drugs & Pharmaceuticals Q2 Results FY27 are the Consolidated quarterly results of Akums Drugs & Pharmaceuticals for July to September 2026, showing revenue of Rs 1,342.39 Cr and net profit of Rs 114.57 Cr, as the Quick Answer summarises.
What is the results date for Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. The company declared the results on 2 November 2026 for the July to September quarter. This results date anchors the comparison with the same quarter last year, which the Financial Highlights table sets out.
What revenue was reported in Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. Akums Drugs & Pharmaceuticals Q2 Results FY27 report Consolidated revenue of Rs 1,342.39 Cr, compared with Rs 1,017.53 Cr a year earlier, so the Performance Analysis section describes a clear rise at the top line.
What net profit was reported in Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. Akums Drugs & Pharmaceuticals reported net profit of Rs 114.57 Cr against Rs 42.70 Cr in the same quarter last year, which means PAT is higher, as the Key Takeaways section notes.
How much YoY growth did revenue show in Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. Revenue showed YoY growth of 31.93%, moving from Rs 1,017.53 Cr to Rs 1,342.39 Cr, while the Performance Analysis adds that net profit grew at a faster rate of 168.31%.
Did net profit rise or fall in Akums Drugs & Pharmaceuticals Q2 Results?
Ans. Net profit rose 168.31% year on year, from Rs 42.70 Cr to Rs 114.57 Cr, so the bottom line moved in the same direction as revenue, as the Key Business Factors section shows.
What was the Operating Profit in Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. Operating Profit was Rs 194.73 Cr against Rs 94.48 Cr in the year-ago quarter, an increase of 106.11%, which appears in the Financial Highlights table and the Performance Analysis.
Are Akums Drugs & Pharmaceuticals Q2 Results consolidated results or standalone results?
Ans. These are consolidated results, so the figures combine the parent company and its group entities. The Conclusion and the Financial Highlights both carry the Consolidated basis for each number quoted.
What business factors shaped Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. The disclosed factors are 31.9% revenue growth, a net profit margin of 8.5% against 4.2%, and a debt-to-assets ratio of 0.02 in FY26, all covered under Key Business Factors.
What are the key risks after Akums Drugs & Pharmaceuticals Q2 Results FY27?
Ans. The listed risks are return on equity of 8.06% in FY26, volatile quarterly net profit between Rs 42.70 Cr and Rs 114.57 Cr, and a fall from 18.30%, detailed in the Key Risks section.
What is the outlook after Akums Drugs & Pharmaceuticals Q2 Results?
Ans. The FY27 outlook depends on later quarters and disclosed sector conditions. Alongside this, the Outlook section names revenue, Operating Profit and net profit as the reference points to follow.
Where can I find the complete Akums Drugs & Pharmaceuticals Q2 Results FY27 data?
Ans. The complete figures appear in the Financial Highlights table on this page, which means readers can compare revenue, Operating Profit and net profit, and the Univest app carries related coverage.
